C_Kili.png

Sven Kili, MD

Cell and Gene Therapy Commercialization Expert

Career Highlights

  • Head of Development for the Cell and Gene Therapy division of GSK Rare Diseases; oversaw teams developing and commercializing gene therapies for a variety of rare genetic disorders including Strimvelis®, the first ex-vivo
    gene therapy to be approved for children with ADA-SCID, Wiskott - Aldrich syndrome (WAS), Metachromatic Leukodystrophy (MLD) and Beta-Thalassemia

  • Senior Director, Cell Therapy and Regenerative Medicine for Sanofi (Genzyme) Biosurgery; led the clinical development, approval and commercialization activities of the first combined ATMP product in the EU for MACI®. Prepared and submitted Advanced Therapy regulatory filings for Australia and the US, including health technology assessments and he was responsible for late stage developments for Carticel® and Epicel® in the US

  • Led the cell therapy activities and oversaw all UK and Irish regulatory functions and was the QPPV for pharmacovigilance for Geistlich Pharma

  • Board member of CCRM, co-chair of the ARM Gene Therapy Steering Committee and co-chair of the ISCT Business models & Investment committee

  • SAB Member for the LGC Group

  • Received an academic appointment as Chair at UCL for the course entitled “MSc in Manufacture and Commercialization of Stem Cell and Gene Therapies” where he leads the course steering committee.

Education

  • MB, ChB; Stellenbosch University

  • MRCS; Royal College of Surgeons of England